Thermo Fisher Scientific launched the PPD CorEvitas Alzheimer’s Disease Registry in December 2025 as a major step forward in gathering real-world evidence for how new Alzheimer’s therapies perform outside controlled clinical trials. The registry operates across more than 500 investigator sites globally and has already enrolled its first patient, bringing together longitudinal data from over 100,000 patients in a coordinated effort to evaluate how approved and emerging Alzheimer’s drugs work in actual clinical practice. This represents one of the largest coordinated efforts to monitor drug safety and effectiveness in the neurodegenerative space, specifically designed to answer questions that traditional drug trials often cannot.
The registry uses a common global protocol to collect standardized, harmonized data from routine clinical practice rather than specialized research settings. This matters because real-world evidence reveals how treatments actually perform when patients take them at home, miss doses, have multiple comorbidities, and receive care at different types of clinics—conditions that don’t exist in the controlled environment of a pivotal trial. This article explains what the registry does, why it was created, how it monitors treatment effectiveness, and what it means for patients and clinicians evaluating Alzheimer’s care options.
Table of Contents
- Why Thermo Fisher Created a Dedicated Alzheimer’s Disease Registry
- How the Registry Collects and Harmonizes Real-World Data
- Advanced Imaging and Biomarker Monitoring in the Registry
- Safety and Effectiveness Evaluation in Real Clinical Practice
- Addressing Unmet Medical Needs and Identifying Research Gaps
- International Collaboration and Data Standardization
- Future Directions for Alzheimer’s Research and Precision Medicine
- Conclusion
Why Thermo Fisher Created a Dedicated Alzheimer’s Disease Registry
The PPD CorEvitas Alzheimer’s Disease Registry fills a gap in how we understand long-term treatment patterns and safety in Alzheimer’s care. Traditional clinical trials are designed to prove whether a drug works under ideal conditions with carefully selected patients—they typically last two to three years and involve regular monitoring. But Alzheimer’s is a slowly progressive disease that unfolds over a decade or more, and questions about how patients actually tolerate and benefit from treatment in everyday life require years of longitudinal follow-up beyond what most trials provide. The registry was created to illuminate these long-term safety signals, identify patterns in how clinicians are using approved therapies, and clarify what unmet medical needs still exist in Alzheimer’s care.
Thermo Fisher’s expansion of the PPD CorEvitas portfolio to include Alzheimer’s reflects the surge in FDA approvals for disease-modifying therapies over the past two years. new monoclonal antibodies targeting amyloid plaque have entered clinical practice, but questions remain about which patients benefit most, which side effects emerge during extended use, and how treatment outcomes correlate with the biological changes we see on imaging. A registry enrolling over 100,000 patients across more than 500 sites positioned internationally creates sufficient statistical power to detect these patterns and support evidence-based decisions about how, when, and for whom to use these therapies. However, even large registries have limitations—they can only observe what clinicians report, not control for unmeasured variables like patient adherence to medications outside the clinic or changes in socioeconomic factors that affect disease progression.
How the Registry Collects and Harmonizes Real-World Data
The PPD CorEvitas registry operates on a longitudinal design, meaning it follows the same patients over time and collects clinician-reported data directly from routine clinical practice. Rather than asking patients to visit research centers for specialized assessments, participating clinicians at neurology practices, memory clinics, and hospital-based cognitive disorder centers report data from regular office visits. This approach generates robust, harmonized data under a common protocol, ensuring that a cognitive assessment done in Cleveland follows the same standardization as one in Copenhagen or Mumbai. Harmonization is critical because it allows researchers to pool data across different countries, health systems, and practice settings without worrying that variations in measurement technique have created artificial differences.
The registry captures longitudinal trajectories—how patients change over months and years—rather than snapshots at a single time point. This longitudinal design is particularly valuable for a slowly progressive disease like Alzheimer’s, where the primary outcome is slowing cognitive decline rather than reversing it. However, longitudinal registries require sustained participation and can suffer from loss to follow-up. Patients may move, stop attending clinic, or become too impaired to participate in data collection, which can introduce bias if those who drop out have systematically different outcomes than those who remain. The registry’s inclusion of over 100,000 patients provides some buffer against this bias, but researchers analyzing the data will need to account for patterns in who continues versus who drops out of the registry.
Advanced Imaging and Biomarker Monitoring in the Registry
One of the registry’s distinctive features is its inclusion of MRI-based evaluations designed to capture the biological effects of treatment on the brain. Specifically, the registry monitors for amyloid-related imaging abnormalities (ARIA)—microscopic bleeding or swelling in the brain—that can occur when monoclonal antibodies targeting amyloid plaque clear plaques too rapidly. This is not a theoretical concern: patients in trials of aducanumab, lecanemab, and donanemab have experienced ARIA, and while many cases are asymptomatic, some patients have had symptomatic events that required hospitalization or intervention. By systematically collecting MRI data across 500+ sites, the registry can quantify how often ARIA occurs, characterize which patients are at highest risk, and correlate imaging findings with cognitive and functional outcomes.
The registry also measures plaque clearance—the reduction in amyloid burden on PET imaging or biofluid markers in blood—as an indicator of treatment effectiveness. Measuring plaque clearance is important because these monoclonal antibodies work by binding to amyloid and facilitating its removal, so evidence that the drug is actually clearing plaque validates that patients are receiving an effective dose. One concrete example: if a patient on lecanemab shows persistent high amyloid burden on imaging six months after starting treatment, that signals either poor drug tolerance (the patient may need dose reduction), poor adherence, or a potential treatment failure that should prompt reconsideration of the clinical approach. The registry’s ability to correlate these imaging measures with cognition outcomes provides crucial real-world validation of whether plaque clearance translates into slowing cognitive decline outside the setting of a controlled trial.
Safety and Effectiveness Evaluation in Real Clinical Practice
The registry’s core mission is to evaluate both safety and effectiveness of approved Alzheimer’s therapies in real clinical practice, which differs fundamentally from trial conditions. In trials, patients are screened extensively, receive standardized doses, come to clinic every few weeks, and are actively monitored for side effects. In real practice, a 78-year-old patient with diabetes, hypertension, and kidney disease might receive the same Alzheimer’s drug at a community neurology practice where follow-up imaging is less frequent and clinician experience with the drug is still developing. The registry captures this reality, documenting how real patients—with comorbidities, polypharmacy, and variable healthcare access—actually tolerate and respond to treatment.
This creates a tradeoff between relevance and control. Real-world data are immediately actionable for clinicians because they reflect the actual patient population they serve, but they lack the experimental controls that make cause-and-effect claims airtight. When the registry reports that patients on lecanemab have a certain rate of ARIA or a certain degree of cognitive decline, those findings are more generalizable to everyday practice than trial results, but they’re also confounded by factors the registry can’t fully control—clinician skill, patient adherence, availability of follow-up imaging, and competing medical conditions. A well-designed registry analysis acknowledges these limitations and uses statistical techniques to adjust for confounding, but the registry itself is generating hypotheses and documenting real-world patterns rather than proving causation.
Addressing Unmet Medical Needs and Identifying Research Gaps
Beyond evaluating approved therapies, the registry is designed to identify unmet medical needs in Alzheimer’s care—questions or problems that current treatments don’t adequately address. For example, if the registry shows that a large proportion of patients with mild cognitive impairment progress to dementia despite taking an approved drug, that signals a need for earlier intervention, combination therapy, or development of drugs targeting different pathways. Similarly, if the registry documents that certain subgroups of patients experience disproportionate ARIA or poor cognitive responses, that identifies candidates for future clinical trials of modified dosing strategies or patient selection criteria. A critical limitation worth highlighting: unmet needs identified in a registry are observational findings, not validated discoveries.
Correlation is not causation, and a finding that women over 75 have worse outcomes on a particular drug might reflect age and female sex as confounders rather than a true sex-specific treatment effect. The registry generates hypotheses that should prompt further investigation in controlled studies, but clinicians and patients should be cautious about drawing firm conclusions from registry data alone. Additionally, the registry can only observe what clinicians report; it cannot detect side effects or outcomes that patients don’t communicate or that clinicians miss. A patient experiencing cognitive side effects from a medication might attribute them to disease progression rather than the drug, leading to underreporting in the registry.
International Collaboration and Data Standardization
The PPD CorEvitas Alzheimer’s Disease Registry is an international, multi-country initiative, meaning it coordinates data collection and sharing across different healthcare systems, regulatory environments, and practice cultures. This global scope is both a strength and a challenge. The strength is that large, diverse datasets can answer questions about treatment effectiveness across different populations and healthcare contexts—important because Alzheimer’s progression, biomarker patterns, and access to cutting-edge therapies vary significantly by region. A patient in a well-resourced tertiary center in the United States has different opportunities for imaging follow-up and specialty care than a patient in a secondary care setting in Europe or Asia, and the registry captures these real-world differences.
For example, the registry might show that amyloid-targeting antibodies are effective at slowing cognitive decline in affluent, well-screened populations but less effective in lower-resource settings where patient identification and follow-up are less stringent. That insight is valuable because it identifies where improved clinical pathways or screening strategies could enhance outcomes. The challenge of international coordination is ensuring data quality, privacy compliance, and comparability when different countries have different electronic health record systems, data governance regulations, and clinical practice standards. The registry’s use of a “common global protocol” means all sites collect the same core data points using standardized definitions, but local variation in implementation is inevitable.
Future Directions for Alzheimer’s Research and Precision Medicine
The registry’s enrollment of its first patient in December 2025 marks the beginning of a multi-year data collection effort that will likely shape how Alzheimer’s therapies are prescribed and optimized over the next decade. As data accumulate, researchers will be able to conduct analyses that trials cannot—long-term follow-up beyond five years, subgroup analyses of specific patient populations (e.g., very advanced dementia, young-onset Alzheimer’s, comorbid Lewy body disease), and evaluation of combination therapy approaches. Future iterations of the registry might incorporate emerging biomarkers like phosphorylated tau in blood, advance in brain imaging, or novel outcome measures that better capture patient-relevant benefits like functional independence or quality of life.
The registry also positions Thermo Fisher and its clinical research partners to generate evidence that could support label expansions or new indications for approved drugs. If the registry demonstrates that an amyloid-targeting antibody is safe and effective in a subpopulation not well-studied in the pivotal trials—such as very elderly patients or those with comorbid cerebrovascular disease—that real-world evidence could support regulatory submissions for expanded use. This represents a shift toward precision medicine in neurodegenerative disease, moving away from one-size-fits-all treatment approaches and toward individualized therapy guided by biomarkers, imaging, and data on how similar patients have responded to treatment.
Conclusion
The Thermo Fisher Scientific PPD CorEvitas Alzheimer’s Disease Registry represents a substantial commitment to understanding how disease-modifying Alzheimer’s therapies perform in real-world clinical practice across more than 500 sites globally. By collecting longitudinal, harmonized data from over 100,000 patients, the registry will document long-term safety profiles, clarify effectiveness in diverse patient populations, and identify gaps in current treatment approaches. The inclusion of advanced imaging monitoring—particularly assessment of amyloid-related imaging abnormalities and plaque clearance—adds biological rigor to the real-world evidence, allowing clinicians and researchers to correlate treatment effects at the imaging and molecular level with clinical outcomes.
For patients with Alzheimer’s disease and their clinicians, the registry’s findings will gradually become part of evidence-based decision-making about which therapies to use, for whom, and how to monitor for efficacy and safety. For researchers and industry, the registry will serve as a platform for identifying unmet needs, generating hypotheses for future trials, and supporting submissions for label expansions or new uses of approved drugs. As the first cohort of enrolled patients completes years of follow-up in the coming years, the data from this registry will provide insights that clinical trials alone cannot deliver.
